NCT03435094View on ClinicalTrials.gov

Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

UnknownOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

February 25, 2018

Primary Completion Date

March 31, 2022

Study Completion Date

December 1, 2022

Conditions
Osteoporosis, Postmenopausal
Interventions
DRUG

Binosto 70Mg Effervescent Tablet

Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.

DRUG

Fosamax 70Mg Tablet

Assess the effect of alendronate 70mg tablet on bone turnover markers and patient reported outcomes.

Trial Locations (2)

1211

RECRUITING

Hôpital Universitaire de Genève, Service des maladies osseuses, Geneva

4055

RECRUITING

Endokrinologische Praxis & Labor, Basel

Sponsors

Lead Sponsor

Labatec Pharma SA
All Listed Sponsors
lead

Labatec Pharma SA

INDUSTRY

NCT03435094 - Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes | Biotech Hunter | Biotech Hunter